Net Remission Rates with Biologic Treatment in Crohn's Disease: A Reappraisal of the Clinical Trial Data

Maia Kayal*, Ryan C. Ungaro, Geoffrey Bader, Jean Frederic Colombel, William J. Sandborn, Carlos Stalgis

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Biologic therapies have greatly advanced the medical care of patients with Crohn's disease (CD); however, up to 50% of patients have no response and up to 80% fail to achieve remission. 1-4 One way to investigate this treatment gap in CD is to look at the "net" remission rates in clinical trials defined as the actual percentage of patients enrolled during induction who are in remission at the end of maintenance. Indeed, most of the seminal clinical trials in CD used a "responder" methodology, where only patients who responded during induction were rerandomized to maintenance.

Original languageEnglish
Pages (from-to)1348-1350
Number of pages3
JournalClinical Gastroenterology and Hepatology
Volume21
Issue number5
DOIs
StatePublished - 2022
Externally publishedYes

Fingerprint

Dive into the research topics of 'Net Remission Rates with Biologic Treatment in Crohn's Disease: A Reappraisal of the Clinical Trial Data'. Together they form a unique fingerprint.

Cite this